GAMMA Investing’s Fate Therapeutics FATE Stock Holding History

GAMMA Investing’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.48K	Hold	1,467	–	–	﹤0.01%	3786
2026 Q2	$3.96K	Buy	1,467 +337	+30%	+$624	﹤0.01%	3569
2026 Q1	$1.36K	Buy	1,130 +908	+409%	+$1.1K	﹤0.01%	3772
2025 Q4	$218	Buy	+222	New	+$267	﹤0.01%	3993
2025 Q1	–	Sell	-626	Closed	-$1.03K	–	3825
2024 Q4	$1.03K	Sell	626 -135	-18%	-$340	﹤0.01%	3417
2024 Q3	$2.66K	Hold	761	–	–	﹤0.01%	2975
2024 Q2	$2.5K	Sell	761 -32	-4%	-$140	﹤0.01%	2824
2024 Q1	$5.82K	Buy	793 +32	+4%	+$198	﹤0.01%	2340
2023 Q4	$4.69K	Buy	+761	New	+$1.8K	﹤0.01%	2265

Other funds holding FATE

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's FATE Position: Q3 2026 in Review

GAMMA Investing held its Fate Therapeutics (FATE) position steady in Q3 2026 at 1,467 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #3786.

GAMMA Investing first reported a position in FATE in Q4 2023 and has held it in 9 quarters since. The position peaked at $5.82K in Q1 2024. 2 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

GAMMA Investing held 1,467 shares of Fate Therapeutics worth $3.48K as of Q3 2026.
GAMMA Investing left its Fate Therapeutics share count unchanged in Q3 2026.
Fate Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3786 holding.
GAMMA Investing first reported a position in Fate Therapeutics in Q4 2023 and has held it in 9 quarters since.
GAMMA Investing's Fate Therapeutics position peaked at $5.82K in Q1 2024.
2 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.